Wise Equity-backed NTC completed the acquisition of ophthalmology business of Pharmathen.

Wise Equity-backed NTC, an international R&D-driven pharmaceutical company, completed the acquisition of ophthalmology business of Pharmathen, a company specializing in innovative life cycle management solutions for branded pharma. Financial terms were not disclosed. "The acquisition of Pharmathen's ophthalmology business is a strategic fit to our portfolio. By integrating therapies to treat glaucoma, we strengthen our commitment to patients who need safe and reliable long-term treatments. With our global partner network, we are ready to internationalize this offering, while presenting our current portfolio to the new partners joining NTC through this transaction. Today, NTC can act as a comprehensive reference partner for companies entering into ophthalmology or expanding existing portfolios," Riccardo Carbucicchio, NTC CEO.